Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model
Abstract Statin treatment may increase the risk of diabetes; there is insufficient data on how statins affect glucose regulation and glycemic control and the effects of statins on liver enzymes related to carbohydrate metabolism have not been fully studied. Therefore, we aimed to compare the effects of the statin derivatives, pravastatin, and rosuvastatin, on carbohydrate metabolism in an experimental diabetic rat model. Female Wistar albino rats were used and diabetes was induced by intraperitoneal injection of streptozotocin. Thereafter, 10 and 20 mg $ kg^{−1 } $$ day^{−1} $ doses of both pravastatin and rosuvastatin were administered by oral gavage to the diabetic rats for 8 weeks. At the end of the experiment, body masses, the levels of fasting blood glucose, serum insulin, insulin resistance (HOMA-IR), liver glycogen, and liver enzymes related to carbohydrate metabolism were measured. Both doses of pravastatin significantly in creased the body mass in diabetic rats, however, rosuvastatin, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $ reduced the body mass signi ficantly. Pravastatin, especially at a dose of 20 mg $ kg^{−1 } $$ day^{−1} $, caused significant increases in liver glycogen synthase and glucose 6-phosphate dehydrogenase levels but significant decreases in the levels of glycogen phosphorylase, lactate dehydrogenase, and glucose-6-phosphatase. Hence, pravastatin partially ameliorated the adverse changes in liver enzymes caused by diabetes and, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $, reduced the fasting blood glucose level and increased the liver glycogen content. However, rosuvastatin, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $, significantly reduced the liver glycogen synthase and pyruvate kinase levels, but increased the glycogen phosphorylase level in diabetic rats. Rosuvastatin, 20 mg $ kg^{−1 } $$ day^{−1 } $dose, caused significant decreases in the body mass and the liver glycogen content of diabetic rats. It can be concluded that pravastatin, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $ is more effective in ameliorating the negative effects of diabetes by modulating carbohydrate metabolism..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Acta pharmaceutica - 74(2024), 1 vom: 01. März, Seite 117-130 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaya, Hacer Kayhan [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2024 Hacer Kayhan Kaya et al., published by Sciendo |
|---|
| doi: |
10.2478/acph-2024-0001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009493212 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009493212 | ||
| 003 | DE-627 | ||
| 005 | 20240331003530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2478/acph-2024-0001 |2 doi | |
| 035 | |a (DE-627)GRUY009493212 | ||
| 035 | |a (DE-B1597)acph-2024-0001-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Kaya, Hacer Kayhan |e verfasserin |0 (orcid)0000-0002-8656-8144 |4 aut | |
| 245 | 1 | 0 | |a Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2024 Hacer Kayhan Kaya et al., published by Sciendo | ||
| 520 | |a Abstract Statin treatment may increase the risk of diabetes; there is insufficient data on how statins affect glucose regulation and glycemic control and the effects of statins on liver enzymes related to carbohydrate metabolism have not been fully studied. Therefore, we aimed to compare the effects of the statin derivatives, pravastatin, and rosuvastatin, on carbohydrate metabolism in an experimental diabetic rat model. Female Wistar albino rats were used and diabetes was induced by intraperitoneal injection of streptozotocin. Thereafter, 10 and 20 mg $ kg^{−1 } $$ day^{−1} $ doses of both pravastatin and rosuvastatin were administered by oral gavage to the diabetic rats for 8 weeks. At the end of the experiment, body masses, the levels of fasting blood glucose, serum insulin, insulin resistance (HOMA-IR), liver glycogen, and liver enzymes related to carbohydrate metabolism were measured. Both doses of pravastatin significantly in creased the body mass in diabetic rats, however, rosuvastatin, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $ reduced the body mass signi ficantly. Pravastatin, especially at a dose of 20 mg $ kg^{−1 } $$ day^{−1} $, caused significant increases in liver glycogen synthase and glucose 6-phosphate dehydrogenase levels but significant decreases in the levels of glycogen phosphorylase, lactate dehydrogenase, and glucose-6-phosphatase. Hence, pravastatin partially ameliorated the adverse changes in liver enzymes caused by diabetes and, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $, reduced the fasting blood glucose level and increased the liver glycogen content. However, rosuvastatin, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $, significantly reduced the liver glycogen synthase and pyruvate kinase levels, but increased the glycogen phosphorylase level in diabetic rats. Rosuvastatin, 20 mg $ kg^{−1 } $$ day^{−1 } $dose, caused significant decreases in the body mass and the liver glycogen content of diabetic rats. It can be concluded that pravastatin, especially at the dose of 20 mg $ kg^{−1 } $$ day^{−1} $ is more effective in ameliorating the negative effects of diabetes by modulating carbohydrate metabolism. | ||
| 700 | 1 | |a Demirtas, Berjan |0 (orcid)0000-0002-0371-6376 |4 aut | |
| 700 | 1 | |a Yokus, Beran |0 (orcid)0000-0003-4585-3712 |4 aut | |
| 700 | 1 | |a Kesim, Dilek Aygün |0 (orcid)0000-0001-5481-1130 |4 aut | |
| 700 | 1 | |a Tasdemir, Ezel |0 (orcid)0000-0003-0108-4149 |4 aut | |
| 700 | 1 | |a Sermet, Abdurrahman |0 (orcid)0000-0001-5579-8310 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica |d Sciendo, 1997 |g 74(2024), 1 vom: 01. März, Seite 117-130 |h Online-Ressource |w (DE-627)GRUY000481424 |w (DE-600)2255569-9 |w (DE-576)281323526 |x 1846-9558 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2024 |g number:1 |g day:01 |g month:03 |g pages:117-130 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2478/acph-2024-0001 |z kostenfrei |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 74 |j 2024 |e 1 |b 01 |c 03 |h 117-130 | ||